New TCR T-cell therapy targeting ROPN1 is a promising candidate for TNBC
May 8, 2023
Around 73,000 women are diagnosed with triple-negative breast cancer (TNBC) every year in the U.S. and EU. TNBC grows and spreads faster than other types of breast cancer; moreover, it has less treatment options, and usually, a worse prognosis.